Causality assessment for liver injury attributable to dietary supplements
Elizabeth Zheng, Victor J. Navarro – 30 March 2017
Novel therapies in the management of acute episodes of hepatic encephalopathy
Rajiv Jalan – 30 March 2017
Potential epidemiologic, economic, and budgetary impacts of current rates of hepatitis C treatment in medicare and non‐medicare populations
John Wittenborn, Joanne Brady, Michelle Dougherty, David Rein – 30 March 2017 – We forecast the health and budgetary impact of hepatitis C (HCV) treatment on the Medicare program based on currently observed rates of treatment among Medicare and non‐Medicare patients and identify the impact of higher rates of treatment among non‐Medicare populations.
Unexpected viral relapses in hepatitis C virus–infected patients diagnosed with hepatocellular carcinoma during treatment with direct‐acting antivirals
Alessandro Soria, Massimiliano Fabbiani, Giuseppe Lapadula, Andrea Gori – 30 March 2017
Grading the range of hepatic encephalopathy from overt to covert: Animals to the rescue!
German Soriano, Jasmohan S. Bajaj – 30 March 2017
Intensive care unit management: Renal replacement therapy, ventilator management, volume assessment, and optimal management of hypotension
Mitra K. Nadim, Jody C. Olson – 30 March 2017
Causality Assessment for Suspected Drug‐Induced Liver Injury in Patients With Underlying Chronic Liver Disease
Lara Dakhoul, Naga Chalasani – 30 March 2017
A functional mammalian target of rapamycin complex 1 signaling is indispensable for c‐Myc‐driven hepatocarcinogenesis
Pin Liu, Mengmeng Ge, Junjie Hu, Xiaolei Li, Li Che, Kun Sun, Lili Cheng, Yuedong Huang, Maria G. Pilo, Antonio Cigliano, Giovanni M. Pes, Rosa M. Pascale, Stefania Brozzetti, Gianpaolo Vidili, Alberto Porcu, Antonio Cossu, Giuseppe Palmieri, Maria C. Sini, Silvia Ribback, Frank Dombrowski, Junyan Tao, Diego F. Calvisi, Ligong Chen, Xin Chen – 30 March 2017 – Amplification and/or activation of the c‐Myc proto‐oncogene is one of the leading genetic events along hepatocarcinogenesis.
Does the dose and type of nonselective beta‐blocker really matter?
Pramod Kumar, Sunil Taneja, Virendra Singh – 30 March 2017